SLRN Investors Have Opportunity to Lead ACELYRIN, Inc. Securities Fraud Lawsuit

SLRN Investors Have Opportunity to Lead ACELYRIN, Inc. Securities Fraud Lawsuit

PR Newswire

LOS ANGELES, Jan. 11, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ACELYRIN, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN).

Class Period: May 4, 2023September 11, 2023
Lead Plaintiff Deadline: January 16, 2024

If you wish to serve as lead plaintiff of the Acelyrin lawsuit, you can submit your contact information at www.glancylaw.com/cases/Acelyrin-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) izokibep was less effective in treating HS than Defendants had led investors to believe; (2) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; (3) as a result, Acelyrin also overstated the Company's business prospects post-IPO; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts 
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/slrn-investors-have-opportunity-to-lead-acelyrin-inc-securities-fraud-lawsuit-302032185.html

SOURCE Glancy Prongay & Murray LLP

Copyright CNW Group 2024